New Perspectives in Cancer Virotherapy: Bringing the Immune System Into Play

• Hanna E , QuickJ, LibuttiSK: The tumour microenvironment: a novel target for cancer therapy.Oral Dis.15(1) , 8–17 (2009).
   PubMed Web of Science ®Google Scholar
• Schuster M , NechanskyA, KircheisR: Cancer immunotherapy.Biotechnol. J.1(2) , 138–147 (2006).
   PubMedGoogle Scholar
• Bierman HR , HammonWM, EddieBU, MeyerKF, ShimkinMB: The effect of virus and bacterial infections on neoplastic diseases.Cancer Res.10(4) , 203–204 (1950).
   Web of Science ®Google Scholar
• Chiocca EA : Oncolytic viruses.Nat. Rev. Cancer2(12) , 938–950 (2002).
   PubMed Web of Science ®Google Scholar
• Russell SJ : RNA viruses as virotherapy agents.Cancer Gene Ther.9(12) , 961–966 (2002).
   PubMed Web of Science ®Google Scholar
• Lorence RM , KatubigBB, ReichardKWet al.: Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy.Cancer Res.54(23) , 6017–6021 (1994).
   PubMed Web of Science ®Google Scholar
• Phuangsab A , LorenceRM, ReichardKW, PeeplesME, WalterRJ: Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration.Cancer Lett.172(1) , 27–36 (2001).
   PubMed Web of Science ®Google Scholar
• Elankumaran S , RockemannD, SamalSK: Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death.J. Virol.80(15) , 7522–7534 (2006).
   PubMed Web of Science ®Google Scholar
• Lorence RM , RobertsMS, O‘NeilJDet al.: Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus.Curr. Cancer Drug Targets7(2) , 157–167 (2007).
   PubMed Web of Science ®Google Scholar
• Laurie SA , BellJC, AtkinsHLet al.: A Phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.Clin. Cancer Res.12(8) , 2555–2562 (2006).
   PubMed Web of Science ®Google Scholar
• Hotte SJ , LorenceRM, HirteHWet al.: An optimized clinical regimen for the oncolytic virus PV701.Clin. Cancer Res.13(3) , 977–985 (2007).
   PubMed Web of Science ®Google Scholar
• Freeman AI , Zakay-RonesZ, GomoriJMet al.: Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.Mol. Ther.13(1) , 221–228 (2006).
   PubMed Web of Science ®Google Scholar
• Yaacov B , EliahooE, LazarIet al.: Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.Cancer Gene Ther.15(12) , 795–807 (2008).
   PubMed Web of Science ®Google Scholar
• Barber GN : Vesicular stomatitis virus as an oncolytic vector.Viral Immunol.17(4) , 516–527 (2004).
   PubMed Web of Science ®Google Scholar
• Lichty BD , PowerAT, StojdlDF, BellJC: Vesicular stomatitis virus: re-inventing the bullet.Trends Mol. Med.10(5) , 210–216 (2004).
   PubMed Web of Science ®Google Scholar
• Noser JA , MaelAA, SakumaRet al.: The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells.Mol. Ther.15(8) , 1531–1536 (2007).
   PubMed Web of Science ®Google Scholar
• Balachandran S , PorosnicuM, BarberGN: Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis.J. Virol.75(7) , 3474–3479 (2001).
   PubMed Web of Science ®Google Scholar
• Ozduman K , WollmannG, PiepmeierJM, van den Pol AN: Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J. Neurosci.28(8) , 1882–1893 (2008).
   PubMed Web of Science ®Google Scholar
• Shi W , TangQ, ChenXet al.: Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer.J. Mol. Med.87(5) , 493–506 (2009).
   PubMed Web of Science ®Google Scholar
• Dhiman N , JacobsonRM, PolandGA: Measles virus receptors: SLAM and CD46.Rev. Med. Virol.14(4) , 217–229 (2004).
   PubMed Web of Science ®Google Scholar
• Gancz D , FishelsonZ: Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development.Mol. Immunol.46(14) , 2794–2800 (2009).
   PubMed Web of Science ®Google Scholar
• Anderson BD , NakamuraT, RussellSJ, PengKW: High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.Cancer Res.64(14) , 4919–4926 (2004).
   PubMed Web of Science ®Google Scholar
• Blechacz B , RussellSJ: Measles virus as an oncolytic vector platform.Curr. Gene Ther.8(3) , 162–175 (2008).
   PubMed Web of Science ®Google Scholar
• Heinzerling L , KunziV, OberholzerPA, KundigT, NaimH, DummerR: Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells.Blood106(7) , 2287–2294 (2005).
   PubMed Web of Science ®Google Scholar
• Mundschau LJ , FallerDV: Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells.Biochimie76(8) , 792–800 (1994).
   PubMed Web of Science ®Google Scholar
• Norman KL , CoffeyMC, HirasawaKet al.: Reovirus oncolysis of human breast cancer.Hum. Gene Ther.13(5) , 641–652 (2002).
   PubMed Web of Science ®Google Scholar
• Alain T , HirasawaK, PonKJet al.: Reovirus therapy of lymphoid malignancies.Blood100(12) , 4146–4153 (2002).
   PubMed Web of Science ®Google Scholar
• Hirasawa K , NishikawaSG, NormanKL, AlainT, KossakowskaA, LeePW: Oncolytic reovirus against ovarian and colon cancer.Cancer Res.62(6) , 1696–1701 (2002).
   PubMed Web of Science ®Google Scholar
• Marcato P , DeanCA, GiacomantonioCA, LeePW: Oncolytic reovirus effectively targets breast cancer stem cells.Mol. Ther.17(6) , 972–979 (2009).
   PubMed Web of Science ®Google Scholar
• Pandha HS , HeinemannL, SimpsonGRet al.: Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.Clin. Cancer Res.15(19) , 6158–6166 (2009).
   PubMed Web of Science ®Google Scholar
• Sei S , MussioJK, YangQEet al.: Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.Mol. Cancer8 , 47 (2009).
   PubMed Web of Science ®Google Scholar
• Vidal L , PandhaHS, YapTAet al.: A Phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.Clin. Cancer Res.14(21) , 7127–7137 (2008).
   PubMed Web of Science ®Google Scholar
• Gollamudi R , GhalibMH, DesaiKKet al.: Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors.Invest. New Drugs DOI: 10.1007/s10637-009-9279-8 (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Prestwich RJ , IlettEJ, ErringtonFet al.: Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.Clin. Cancer Res.15(13) , 4374–4381 (2009).
   PubMed Web of Science ®Google Scholar
• Myers R , GreinerS, HarveyMet al.: Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer.Cancer Gene Ther.12(7) , 593–599 (2005).
   PubMed Web of Science ®Google Scholar
• Toyoda H , YinJ, MuellerS, WimmerE, CelloJ: Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model.Cancer Res.67(6) , 2857–2864 (2007).
   PubMed Web of Science ®Google Scholar
• Angelova AL , AprahamianM, BalboniGet al.: Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: in vitro and in vivo studies.Mol. Ther.17(7) , 1164–1172 (2009).
   PubMed Web of Science ®Google Scholar
• Nawa A , LuoC, ZhangLet al.: Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.Curr. Gene Ther.8(3) , 208–221 (2008).
   PubMed Web of Science ®Google Scholar
• Kimata H , ImaiT, KikumoriTet al.: Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.Ann. Surg. Oncol.13(8) , 1078–1084 (2006).
   PubMed Web of Science ®Google Scholar
• Fujimoto Y , MizunoT, SugiuraSet al.: Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.Acta Otolaryngol.126(10) , 1115–1117 (2006).
   PubMed Web of Science ®Google Scholar
• Fielding AK : Measles as a potential oncolytic virus.Rev. Med. Virol.15(2) , 135–142 (2005).
   PubMed Web of Science ®Google Scholar
• Thorne SH , HwangTH, KirnDH: Vaccinia virus and oncolytic virotherapy of cancer.Curr. Opin. Mol. Ther.7(4) , 359–365 (2005).
   PubMedGoogle Scholar
• Lin E , NemunaitisJ: Oncolytic viral therapies.Cancer Gene Ther.11(10) , 643–664 (2004).
   PubMed Web of Science ®Google Scholar
• Kanerva A , HemminkiA: Modified adenoviruses for cancer gene therapy.Int. J. Cancer110(4) , 475–480 (2004).
   PubMed Web of Science ®Google Scholar
• Waehler R , RussellSJ, CurielDT: Engineering targeted viral vectors for gene therapy.Nat. Rev. Genet.8(8) , 573–587 (2007).
   PubMed Web of Science ®Google Scholar
• Menotti L , NicolettiG, GattaVet al.: Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.Proc. Natl Acad. Sci. USA106(22) , 9039–9044 (2009).
   PubMed Web of Science ®Google Scholar
• Piao Y , JiangH, AlemanyRet al.: Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity.Cancer Gene Ther.16(3) , 256–265 (2009).
   PubMed Web of Science ®Google Scholar
• Coughlan L , VallathS, SahaAet al.: In vivo retargeting of adenovirus type 5 to αvβ6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.J. Virol.83(13) , 6416–6428 (2009).
   PubMed Web of Science ®Google Scholar
• Jing Y , TongC, ZhangJet al.: Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.Cancer Res.69(4) , 1459–1468 (2009).
   PubMed Web of Science ®Google Scholar
• Liu C , HasegawaK, RussellSJ, SadelainM, PengKW: Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.Prostate69(10) , 1128–1141 (2009).
   PubMed Web of Science ®Google Scholar
• Crompton AM , KirnDH: From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development.Curr. Cancer Drug Targets7(2) , 133–139 (2007).
   PubMed Web of Science ®Google Scholar
• Wiman KG : Strategies for therapeutic targeting of the p53 pathway in cancer.Cell Death Differ.13(6) , 921–926 (2006).
   PubMed Web of Science ®Google Scholar
• O‘Shea CC , JohnsonL, BagusBet al.: Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.Cancer Cell6(6) , 611–623 (2004).
   PubMed Web of Science ®Google Scholar
• Nettelbeck DM : Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.J. Mol. Med.86(4) , 363–377 (2008).
   PubMed Web of Science ®Google Scholar
• Kamizono J , NaganoS, MurofushiYet al.: Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication.Cancer Res.65(12) , 5284–5291 (2005).
   PubMed Web of Science ®Google Scholar
• Schepelmann S , SpringerCJ: Viral vectors for gene-directed enzyme prodrug therapy.Curr. Gene Ther.6(6) , 647–670 (2006).
   PubMed Web of Science ®Google Scholar
• Guffey MB , ParkerJN, LuckettWS Jr et al.: Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther.14(1) , 45–56 (2007).
   PubMed Web of Science ®Google Scholar
• Chalikonda S , KivlenMH, O‘MalleyMEet al.: Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.Cancer Gene Ther.15(2) , 115–125 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang X , KomakiR, WangL, FangB, ChangJY: Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus.Clin. Cancer Res.14(9) , 2813–2823 (2008).
   PubMed Web of Science ®Google Scholar
• Yang M , CaoX, YuMCet al.: Potent antitumor efficacy of ST13 for colorectal cancer mediated by oncolytic adenovirus via mitochondrial apoptotic cell death.Hum. Gene Ther.19(4) , 343–353 (2008).
   PubMed Web of Science ®Google Scholar
• Prestwich RJ , HarringtonKJ, PandhaHS, VileRG, MelcherAA, ErringtonF: Oncolytic viruses: a novel form of immunotherapy.Expert Rev. Anticancer Ther.8(10) , 1581–1588 (2008).
   PubMed Web of Science ®Google Scholar
• Errington F , SteeleL, PrestwichRet al.: Reovirus activates human dendritic cells to promote innate antitumor immunity.J. Immunol.180(9) , 6018–6026 (2008).
   PubMed Web of Science ®Google Scholar
• Gauvrit A , BrandlerS, Sapede-PerozC, BoisgeraultN, TangyF, GregoireM: Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.Cancer Res.68(12) , 4882–4892 (2008).
   PubMed Web of Science ®Google Scholar
• Bianchi ME , ManfrediAA: High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.Immunol. Rev.220(1) , 35–46 (2007).
   PubMedGoogle Scholar
• Janke M , PeetersB, de Leeuw O et al.: Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther.14(23) , 1639–1649 (2007).
   PubMed Web of Science ®Google Scholar
• Thorne SH , HwangTH, O‘GormanWEet al.: Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.J. Clin. Invest.117(11) , 3350–3358 (2007).
   PubMed Web of Science ®Google Scholar
• Park BH , HwangT, LiuTCet al.: Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a Phase I trial.Lancet Oncol.9(6) , 533–542 (2008).
   PubMed Web of Science ®Google Scholar
• Lei N , ShenFB, ChangJHet al.: An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors.Cancer Gene Ther.16(1) , 33–43 (2009).
   PubMed Web of Science ®Google Scholar
• Chang J , ZhaoX, WuXet al.: A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.Cancer Biol. Ther.8(8) , 676–682 (2009).
   PubMed Web of Science ®Google Scholar
• Zamarin D , VigilA, KellyK, Garcia-SastreA, FongY: Genetically engineered Newcastle disease virus for malignant melanoma therapy.Gene Ther.16(6) , 796–804 (2009).
   PubMed Web of Science ®Google Scholar
• Shin EJ , WannaGB, ChoiBet al.: Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.Laryngoscope117(2) , 210–214 (2007).
   PubMed Web of Science ®Google Scholar
• Ino Y , SaekiY, FukuharaH, TodoT: Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7–1 results in enhanced antitumor efficacy.Clin. Cancer Res.12(2) , 643–652 (2006).
   PubMed Web of Science ®Google Scholar
• Zheng JN , PeiDS, MaoLJet al.: Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis.Cancer Gene Ther.17(1) , 28–36 (2009).
   Web of Science ®Google Scholar
• Zhang KJ , WangYG, CaoXet al.: Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus.Hum. Gene Ther.20(8) , 818–830 (2009).
   PubMed Web of Science ®Google Scholar
• Post DE , SandbergEM, KyleMMet al.: Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.Cancer Res.67(14) , 6872–6881 (2007).
   PubMed Web of Science ®Google Scholar
• Liu J , WennierS, ReinhardM, RoyE, MacNeillA, McFaddenG: Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits.J. Virol.83(11) , 5933–5938 (2009).
   PubMed Web of Science ®Google Scholar
• Shashkova EV , SpencerJF, WoldWS, DoroninK: Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.Mol. Ther.15(3) , 598–607 (2007).
   Web of Science ®Google Scholar
• Brin E , AtencioI, HelmichBK, ManevalD, LafaceD: Adenovirus delivery provides extended interferon-alpha exposure and augments treatment of metastatic carcinoma.Cancer Gene Ther.13(7) , 664–675 (2006).
   PubMed Web of Science ®Google Scholar
• Ohashi M , YoshidaK, KushidaMet al.: Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer.Br. J. Cancer93(4) , 441–449 (2005).
   PubMed Web of Science ®Google Scholar
• Lapteva N , AldrichM, WeksbergDet al.: Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.J. Immunother.32(2) , 145–156 (2009).
   PubMed Web of Science ®Google Scholar
• Chen T , GuoJ, HanC, YangM, CaoX: Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway.J. Immunol.182(3) , 1449–1459 (2009).
   PubMed Web of Science ®Google Scholar
• Tsan MF , GaoB: Heat shock proteins and immune system.J. Leukoc. Biol.85(6) , 905–910 (2009).
   PubMed Web of Science ®Google Scholar
• Bendz H , RuhlandSC, PandyaMJet al.: Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling.J. Biol. Chem.282(43) , 31688–31702 (2007).
   PubMed Web of Science ®Google Scholar
• Obeid M , TesniereA, GhiringhelliFet al.: Calreticulin exposure dictates the immunogenicity of cancer cell death.Nat. Med.13(1) , 54–61 (2007).
   PubMed Web of Science ®Google Scholar
• Kepp O , SenovillaL, GalluzziLet al.: Viral subversion of immunogenic cell death.Cell Cycle8(6) , 860–869 (2009).
   PubMed Web of Science ®Google Scholar
• Shi Y , EvansJE, RockKL: Molecular identification of a danger signal that alerts the immune system to dying cells.Nature425(6957) , 516–521 (2003).
   PubMed Web of Science ®Google Scholar
• Yu M , WangH, DingAet al.: HMGB1 signals through Toll-like receptor (TLR) 4 and TLR2.Shock26(2) , 174–179 (2006).
   PubMed Web of Science ®Google Scholar
• Chen K , HuangJ, GongW, IribarrenP, DunlopNM, WangJM: Toll-like receptors in inflammation, infection and cancer.Int. Immunopharmacol.7(10) , 1271–1285 (2007).
   PubMed Web of Science ®Google Scholar
• Ramakrishna E , WollerN, MundtBet al.: Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.Cancer Res.69(4) , 1448–1458 (2009).
   PubMed Web of Science ®Google Scholar
• Ghulam Muhammad AK , CandolfiM, KingGDet al.: Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.Clin. Cancer Res.15(19) , 6113–6127 (2009).
   PubMed Web of Science ®Google Scholar
• Raykov Z , GrekovaS, LeuchsB, AprahamianM, RommelaereJ: Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity.Int. J. Cancer122(12) , 2880–2884 (2008).
   PubMed Web of Science ®Google Scholar
• Lapteva N , AldrichM, RollinsLet al.: Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.Mol. Ther.17(9) , 1626–1636 (2009).
   PubMed Web of Science ®Google Scholar
• Dzojic H , LoskogA, TottermanTH, EssandM: Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.Prostate66(8) , 831–838 (2006).
   PubMed Web of Science ®Google Scholar
• Fernandes MS , GomesEM, ButcherLDet al.: Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.Clin. Cancer Res.15(15) , 4847–4856 (2009).
   PubMed Web of Science ®Google Scholar
• Gomes EM , RodriguesMS, PhadkeAPet al.: Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.Clin. Cancer Res.15(4) , 1317–1325 (2009).
   PubMed Web of Science ®Google Scholar
• Kottke T , ThompsonJ, DiazRMet al.: Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.Clin. Cancer Res.15(2) , 561–569 (2009).
   PubMed Web of Science ®Google Scholar
• Di Paolo NC , TuveS, NiS, HellstromKE, HellstromI, LieberA: Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.Cancer Res.66(2) , 960–969 (2006).
   PubMed Web of Science ®Google Scholar
• Qiao J , WangH, KottkeTet al.: Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.Clin. Cancer Res.14(1) , 259–269 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas MA , SpencerJF, TothK, SagartzJE, PhillipsNJ, WoldWS: Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.Mol. Ther.16(10) , 1665–1673 (2008).
   PubMed Web of Science ®Google Scholar
• Fulci G , BreymannL, GianniDet al.: Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.Proc. Natl Acad. Sci. USA103(34) , 12873–12878 (2006).
   PubMed Web of Science ®Google Scholar
• Mader EK , MaeyamaY, LinYet al.: Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.Clin. Cancer Res.15(23) , 7246–7255 (2009).
   PubMed Web of Science ®Google Scholar
• Iankov ID , MsaouelP, AllenCet al.: Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.Breast Cancer Res Treat. DOI: 10.1007/s10549-009-0602-z (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Ilett EJ , PrestwichRJ, KottkeTet al.: Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.Gene Ther.16(5) , 689–699 (2009).
   PubMed Web of Science ®Google Scholar
• Willmon C , HarringtonK, KottkeT, PrestwichR, MelcherA, VileR: Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.Mol. Ther.17(10) , 1667–1676 (2009).
   PubMed Web of Science ®Google Scholar
• Prestwich RJ , ErringtonF, DiazRMet al.: The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.Hum. Gene Ther.20(10) , 1119–1132 (2009).
   PubMed Web of Science ®Google Scholar
• Post DE , FulciG, ChioccaEA, Van Meir EG: Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr. Gene Ther.4(1) , 41–51 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar S , GaoL, YeagyB, ReidT: Virus combinations and chemotherapy for the treatment of human cancers.Curr. Opin. Mol. Ther.10(4) , 371–379 (2008).
   PubMed Web of Science ®Google Scholar
• Nguyen TL , TumilasciVF, SinghroyD, ArguelloM, HiscottJ: The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.Cell Microbiol.11(6) , 889–897 (2009).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Mayo Clinic: clinical trials http://clinicaltrials.mayo.edu
   Google Scholar
• Oncolytics Biotech Inc.: clinical trials www.oncolyticsbiotech.com/clinical.html
   Google Scholar